scholarly journals Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis

Oncotarget ◽  
2016 ◽  
Vol 7 (28) ◽  
pp. 44545-44557 ◽  
Author(s):  
Chenjing Zhu ◽  
Xuelei Ma ◽  
Yuanyuan Hu ◽  
Linghong Guo ◽  
Bo Chen ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cancer Therapy ◽  
Meta Analysis ◽  
Safety And Efficacy ◽  
Efficacy Profile

Safety and Efficacy Profile of Neratinib: A Systematic Review and Meta-Analysis of 23 Prospective Clinical Trials

2018 ◽  
Vol 39 (1) ◽  
pp. 27-43 ◽  
Author(s):  
Zhihang Tao ◽  
Stanley Xiangyu Li ◽  
Kai Shen ◽  
Yunuo Zhao ◽  
Hao Zeng ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Meta Analysis ◽  
Safety And Efficacy ◽  
Efficacy Profile

scholarly journals Safety and efficacy profile of cyclin‐dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta‐analysis of clinical trials

2019 ◽  
Vol 8 (4) ◽  
pp. 1389-1400 ◽  
Author(s):  
Linghong Guo ◽  
Yuanyuan Hu ◽  
Xi Chen ◽  
Qingfang Li ◽  
Benling Wei ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Cancer Therapy ◽  
Meta Analysis ◽  
Safety And Efficacy ◽  
Cyclin Dependent Kinases ◽  
Efficacy Profile

scholarly journals Safety and Efficacy of Rituximab in Systemic Sclerosis: A Systematic Review and Meta-analysis

2019 ◽  
Author(s):  
Rui Tang ◽  
Jiangfan Yu ◽  
Yaqian Shi ◽  
Puyu Zou ◽  
Zhuotong Zeng ◽  
...  
Keyword(s):  
Systematic Review ◽  
Systemic Sclerosis ◽  
Adverse Events ◽  
Pulmonary Function ◽  
Web Of Science ◽  
Meta Analysis ◽  
Lung Involvement ◽  
Skin Involvement ◽  
Safety And Efficacy ◽  
Efficacy Profile

Abstract Background: Rituximab has been widely proposed to treat systemic sclerosis (SSc) by depletion of pathogenic B cells. Nonetheless, the clinical benefit of Rituximab in SSc remains contentious. Objective: This meta-analysis was conducted to systematically evaluate the safety and efficacy profile of Rituximab in SSc patients. Methods: We performed a systematic online query in PubMed, Cochrane, and Web of science. Available studies about the assessment of Rituximab in SSc patients were comprehensively reviewed and investigated. Results: In total, 14 studies comprising 597 participants were enrolled in our analysis. Pooled results showed the durable improvement of mRSS for skin involvement (∆mRSS: 7.00 at 6-month, 9.70 at 12-month, and 10.93 at 24-month), while FVC (∆FVC: -0.69 at 6-month, -2.62 at 12-month, -0.67 at 24-month) and DLCO (∆DLCO -2.39 at 6-month, -3.28 at 12-month, -0.79 at 24-month) for lung involvement remain stable in SSc patients after Rituximab treatment. And safety profile of Rituximab-related adverse events rate was 12% in the pooled result. Conclusion: The pooled results of this meta-analysis indicated that Rituximab was well-tolerated, and it was able to generate improvement of cutaneous function and stabilization of pulmonary function in SSc patients.

Safety and efficacy of UV application for superficial infections in humans: A systematic review and meta-analysis

2021 ◽  
Author(s):  
Sanjay Marasini ◽  
Alexis Ceecee Zhang ◽  
Simon J. Dean ◽  
Simon Swift ◽  
Jennifer P. Craig
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Safety And Efficacy
Sign in / Sign up

Export Citation Format

Share Document